Abstract
Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention
Volume: 11 Issue: 2
Author(s): Chiara Cavallino, Matteo Santagostino, Emanuela Facchini, Virginia Di Ruocco and Andrea Rognoni
Affiliation:
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Export Options
About this article
Cite this article as:
Cavallino Chiara, Santagostino Matteo, Facchini Emanuela, Ruocco Virginia Di and Rognoni Andrea, Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020004
DOI https://dx.doi.org/10.2174/1871525711311020004 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Preface: MicroRNA as Disease Biomarkers
MicroRNA Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) A Review on Recent Patents in Digital Processing for Cardiac Electric Signals (I): From Basic Systems to Arrhythmia Analysis
Recent Patents on Biomedical Engineering (Discontinued) Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents
Current Cardiology Reviews Gene Therapy Approaches for the Prevention of Restenosis
Current Vascular Pharmacology Editorial (Hot Topic: Vascular Remodeling)
Current Vascular Pharmacology Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology